Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Double Dose QIV in Pregnant Women in Kenya
NCT01810731Phase 3Withdrawn
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Apr 2014
- Primary completion
- Apr 2014
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza virus quadrivalent inactivated vaccine in influenza (3 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoints: Proportion of women with an appropriate rise in Hemagglutination Inhibition (HI) titers at Day 28, Proportion of infants with HI titers >= 40 in cord blood and 1 more. Planned start Apr 2014; status: withdrawn.
02
Drugs
influenza virus quadrivalent inactivated vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01810731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810731.